Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-26-002469

Chief Development Officer sold 2,840 shares at $30.05 ($85,342)

  • Chief Development Officer acquired 9,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Yeleswaram Krishnaswamy Chief Development Officer 2025-12-31 Grant or award +9,000 299,831 D
Yeleswaram Krishnaswamy Chief Development Officer 2025-12-31 Sale −2,840 $30.05 $85,342 296,991 D
Open-market sales · 2,840 sh · avg $30.05 · $85,342
Loading xslF345X05/ownership.xml…